Zeeneldin Ahmed Abdelmabood, Gaber Ayman Abdelsamee, Taha Fatma Mohamed
Medical Oncology/Hematology, National Cancer Institute, Cairo University, Cairo, Egypt.
J Egypt Natl Canc Inst. 2012 Sep;24(3):133-7. doi: 10.1016/j.jnci.2012.06.003. Epub 2012 Jul 31.
To estimate the effect of fasting during Ramadan (the ninth lunar month) on adherence to oral hormonal therapies (OHT) among breast cancer (BC) patients.
During Ramadan 2010, 139 BC patients were interviewed at the Egyptian National Cancer Institute. They were asked about fasting as well as intake of OHT in Ramadan and in the preceding month.
The median age was 50years and most patients were postmenopausal with good performance status and non-metastatic disease. The median number of fasting days was 18% and 93% of patients were fasting 80% or more of Ramadan. Tamoxifen and aromatase inhibitors were used in 64% and 36%, respectively. Adherence to OHT during Ramadan and its preceding month were 94.2% and 95.7%, respectively (p=0.77). In univariate analysis, non-adherence prior to Ramadan and shorter duration of OHT were predictors of non-adherence during Ramadan (P<0.001, 0.003, respectively). Fasting, age, performance status, presence of metastases and type of hormonal therapy were not good predictors of adherence.
While most of patients receiving OHT for BC are fasting during Ramadan, this does not negatively impact compliance with treatment.
评估斋月（农历九月）禁食对乳腺癌（BC）患者口服激素治疗（OHT）依从性的影响。
在2010年斋月期间，对埃及国家癌症研究所的139例BC患者进行了访谈。询问了他们在斋月及前一个月的禁食情况以及OHT的服用情况。
中位年龄为50岁，大多数患者为绝经后，身体状况良好且无转移性疾病。禁食天数的中位数为18%，93%的患者在斋月期间禁食天数达到或超过80%。分别有64%和36%的患者使用他莫昔芬和芳香化酶抑制剂。斋月期间及前一个月OHT的依从性分别为94.2%和95.7%（p = 0.77）。在单因素分析中，斋月前不依从以及OHT疗程较短是斋月期间不依从的预测因素（分别为P < 0.001，0.003）。禁食、年龄、身体状况、是否存在转移以及激素治疗类型并非依从性的良好预测因素。
虽然大多数接受BC的OHT治疗的患者在斋月期间禁食，但这对治疗依从性没有负面影响。
